Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study of VX-809 to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of VX-809 in Cystic Fibrosis Subjects Homozygous for the ∆F508-CFTR Gene Mutation
Brief Summary: The primary objective of the study was to evaluate the safety and tolerability of VX-809 in participants with cystic fibrosis (CF) who are homozygous for the F508del mutation on the CF transmembrane conductance regulator (CFTR) gene.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: VX-809, 25 mg; Type: EXPERIMENTAL; Interventions: Drug: VX-809 | Arm Label: VX-809, 50 mg; Type: EXPERIMENTAL; Interventions: Drug: VX-809 | Arm Label: VX-809, 100 mg; Type: EXPERIMENTAL; Interventions: Drug: VX-809 | Arm Label: VX-809, 200 mg; Type: EXPERIMENTAL; Interventions: Drug: VX-809 | Intervention Type: DRUG; Name: VX-809; Assigned to Arm(s): VX-809, 100 mg, VX-809, 200 mg, VX-809, 25 mg, VX-809, 50 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Treatment Period 1: LUM/IVA to LUM/IVA; Type: EXPERIMENTAL; Interventions: Drug: LUM/IVA | Arm Label: Treatment Period 1: Placebo (PBO) to LUM/IVA; Type: EXPERIMENTAL; Interventions: Drug: LUM/IVA | Arm Label: Treatment Period 1: Observational Cohort; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Treatment Period 2: LUM/IVA; Type: EXPERIMENTAL; Interventions: Drug: LUM/IVA | Intervention Type: DRUG; Name: LUM/IVA; Assigned to Arm(s): Treatment Period 1: LUM/IVA to LUM/IVA, Treatment Period 1: Placebo (PBO) to LUM/IVA | Intervention Type: DRUG; Name: LUM/IVA; Assigned to Arm(s): Treatment Period 2: LUM/IVA
C: Arm Label: Part 1: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Part 1: VX-121/TEZ/VX-561 TC - Low Dose; Type: EXPERIMENTAL; Interventions: Drug: VX-121, Drug: TEZ, Drug: VX-561 | Arm Label: Part 1: VX-121/TEZ/VX-561 TC - Medium Dose; Type: EXPERIMENTAL; Interventions: Drug: VX-121, Drug: TEZ, Drug: VX-561 | Arm Label: Part 1: VX-121/TEZ/VX-561 TC - High Dose; Type: EXPERIMENTAL; Interventions: Drug: VX-121, Drug: TEZ, Drug: VX-561 | Arm Label: Part 2: TEZ/IVA; Type: ACTIVE_COMPARATOR; Interventions: Drug: TEZ/IVA, Drug: IVA | Arm Label: Part 2: VX-121/TEZ/VX-561 TC - High Dose; Type: EXPERIMENTAL; Interventions: Drug: VX-121, Drug: TEZ, Drug: VX-561 | Intervention Type: DRUG; Name: VX-121; Assigned to Arm(s): Part 1: VX-121/TEZ/VX-561 TC - High Dose, Part 1: VX-121/TEZ/VX-561 TC - Low Dose, Part 1: VX-121/TEZ/VX-561 TC - Medium Dose, Part 2: VX-121/TEZ/VX-561 TC - High Dose | Intervention Type: DRUG; Name: TEZ; Assigned to Arm(s): Part 1: VX-121/TEZ/VX-561 TC - High Dose, Part 1: VX-121/TEZ/VX-561 TC - Low Dose, Part 1: VX-121/TEZ/VX-561 TC - Medium Dose, Part 2: VX-121/TEZ/VX-561 TC - High Dose | Intervention Type: DRUG; Name: VX-561; Assigned to Arm(s): Part 1: VX-121/TEZ/VX-561 TC - High Dose, Part 1: VX-121/TEZ/VX-561 TC - Low Dose, Part 1: VX-121/TEZ/VX-561 TC - Medium Dose, Part 2: VX-121/TEZ/VX-561 TC - High Dose | Intervention Type: DRUG; Name: TEZ/IVA; Assigned to Arm(s): Part 2: TEZ/IVA | Intervention Type: DRUG; Name: IVA; Assigned to Arm(s): Part 2: TEZ/IVA | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Part 1: Placebo
D: Arm Label: Lumacaftor/Ivacaftor (LUM/IVA); Type: EXPERIMENTAL; Interventions: Drug: Lumacaftor, Drug: Ivacaftor | Intervention Type: DRUG; Name: Lumacaftor; Assigned to Arm(s): Lumacaftor/Ivacaftor (LUM/IVA) | Intervention Type: DRUG; Name: Ivacaftor; Assigned to Arm(s): Lumacaftor/Ivacaftor (LUM/IVA)

Answer: A